In Brief: Toxikon
This article was originally published in The Gray Sheet
Executive SummaryToxikon: FDA tells environmental sciences and toxicology testing firm that its response to an April 10 agency warning letter ("The Gray Sheet" May 1, I&W-11) satisfactorily addresses all issues raised by the agency. In a May 4 letter, FDA says that the information provided by the company in an April 12 correspondence "satisf[ies] our concerns expressed in the warning letter." Toxikon reports that "no corrective actions were required"...
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.